^
Association details:
| Biomarker: | HER-2 778insGSP |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
Published date:
05/03/2022
Excerpt:
We observed that two patients bearing HER2 mutations (Patient #1 bearing S310F and V777L mutations, Patient #2 bearing 778insGSP mutation) achieved a durable partial response to Trastuzumab combined with Everolimus. In vitro experiments showed that T47D and MCF7 cells overexpressing these HER2 mutants (S310F, V777L, 778insGSP and L755S) were sensitive to HER2-targeted therapies combined with the mTOR inhibitor Everolimus.
DOI:
10.1016/j.tranon.2022.101444
